99%+ COA
3rd party tested99%+ purityResearch use only
Shop / GLP-3(RT)
Triple-action metabolic compound · Locked in Winter · 35% off
GLP-3 (RT)
2381089-83-2GLP-3
A 39-amino acid triple agonist peptide targeting GIP, GLP-1, and glucagon receptors, studied for metabolic regulation and body composition in clinical research. Premium research peptide.
Mass
Quantity
1
$380$250
Bundle & save
Order within 20h 25m · ships tomorrow
Cutoff 2:00 PM PT
Arrives Tue, Sep 22 – Thu, Sep 24
Free standard shipping on orders over $150
Free shipment protection
Lost, stolen, or damaged? We replace it.
Overnight and 2-day options
Pick your speed at checkout
Metabolic pathway research compounds
Frequently researched together
Verified test results
Every batch, independently verified.
Lots are sourced to a 99%+ identity standard and third-party tested. Certificates of analysis are released on request — the same paperwork, signed, for the vial you get.
Certificate of analysis
99%+
Identity purity by HPLC
- Appearance
- Lyophilized
- Identity
- Confirmed
- Documentation
- On request
Benefits you may experience
- Cuts food noise and late-night cravings
- Supports serious fat loss and recomposition
- Helps the body use stored fat for fuel
- Steadier energy through the day
- Pairs hard with lifting + high protein
- Makes a deficit actually stick
Technical specifications
Compound information
Molecular profile
What is GLP-3 (RT)?
- Type
- Lyophilized powder
- CAS
- 2381089-83-2
- Purity
- 99%+ identity
- Mass
- 40mg
Storage
Stability information
- Lyophilized
- −20°C, protect from light
- Reconstituted
- 2–8°C
- Mix water
- Bacteriostatic water (Siix H2O)
- Use
- Research use only
Peer-reviewed literature
The research behind this compound
Educational references from published literature. Not medical advice. Not a claim that this product treats or prevents disease.
New England Journal of Medicine · 2023
Triple Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial
The Lancet · 2023
Retatrutide for People with Type 2 Diabetes: A Phase 2 Trial
Nature Medicine · 2024
Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease
Lancet Diabetes & Endocrinology · 2024
Effects of Retatrutide on Body Composition
For research use only. Not for human consumption. Not medical advice. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease. Checkout with Zelle or Apple Pay. Text (661) 446-9637 with questions. COAs available upon request.